Esophageal cancer proliferation is mediated by cytochrome P450 2C9 (CYP2C9)

Prostaglandins and Other Lipid Mediators

Volumn 94, Issue 1-2, 2011, Pages 25-33

  Schmelzle, Moritz ^a   Dizdar, Levent ^a   Matthaei, Hanno ^a   Baldus, Stephan E ^a   Wolters, Judith ^a   Lindenlauf, Nina ^a   Bruns, Ingmar ^a   Cadeddu, Ron Patrick ^a   Kröpil, Feride ^a   Topp, Stefan A ^a   Schulte Am Esch II, Jan ^a   Eisenberger, Claus F ^a   Knoefel, Wolfram T ^a   Stoecklein, Nikolas H ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

11,12 EET; CYP2C9; Cytochrome P450; Esophageal cancer; Tumor proliferation

Indexed keywords

11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; CYTOCHROME P450 2C9; EPOXYICOSATRIENOIC ACID; KI 67 ANTIGEN; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS MUCOSA; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR GROWTH;

8,11,14-EICOSATRIENOIC ACID; ARYL HYDROCARBON HYDROXYLASES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; G0 PHASE; G1 PHASE; HUMANS; IMMUNOHISTOCHEMISTRY;

EID: 79551545630     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2010.12.001     Document Type: Article

References (30)

1. S.M. Jeurissen, J.J. Bogaards, and M.G. Boersma Human cytochrome p450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1′-hydroxymethyleugenol Chem Res Toxicol 19 January (1) 2006 111 116
2. C.X. Yang, K. Matsuo, Z.M. Wang, and K. Tajima Phase I/II enzyme gene polymorphisms and esophageal cancer risk: a meta-analysis of the literature World J Gastroenterol 11 17 2005 2531 2838
3. T. Su, Z. Bao, Q.Y. Zhang, T.J. Smith, J.Y. Hong, and X. Ding Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone Cancer Res 60 18 2000 5074 5079
4. S.J. London, T. Sullivan-Klose, A.K. Daly, and J.R. Idle Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County Pharmacogenetics 7 5 1997 401 404
5. G.J. Tranah, A.T. Chan, E. Giovannucci, J. Ma, C. Fuchs, and D.J. Hunter Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses' Health Study and the Physicians' Health Study Mol Carcinog 44 1 2005 21 30
6. J.G. Jiang, C.L. Chen, and J.W. Card Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors Cancer Res 65 June (11) 2005 4707 4715
7. D.C. Zeldin Epoxygenase pathways of arachidonic acid metabolism J Biol Chem 276 2001 36059 36062
8. J.H. Capdevila, J.R. Falck, and R.C. Harris Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxyge-nase J Lipid Res 41 2000 163 181
9. T. Thum, V.J. Erpenbeck, J. Moeller, J.M. Hohlfeld, N. Krug, and J. Borlak Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers Environ Health Perspect 114 November (11) 2006 1655 1661
10. S.J. Hughes, M.A. Morse, and C.M. Weghorst Cytochrome P450 are expressed in proliferating cells in Barrett's metaplasia Neoplasia 1 June (2) 1999 145 153
11. G.I. Murray, D. Shaw, and R.J. Weaver Cytochrome P450 expression in oesophageal cancer Gut 35 1994 599 603
12. A.E. Enayetallah, R.A. French, and D.F. Grant Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9/19 and 2J2 in human malignant neoplasms J Mol Histol 37 3-4 2006 133 141
13. M. Potente, U.R. Michaelis, B. Fisslthaler, R. Busse, and I. Fleming Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1 J Biol Chem 277 May (18) 2002 15671 15676
14. U. Yasar, E. Eliasson, M.L. Dahl, I. Johansson, M. Ingelman-Sundberg, and F. Sjöqvist Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population Biochem Biophys Res Commun 254 January (3) 1999 628 631
15. T.S. Klose, J.A. Blaisdell, and J.A. Goldstein Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs J Biochem Mol Toxicol 13 6 1999 289 295
16. M. Wu, S. Chen, and X. Wu Differences in cytochrome P450 2C19 (CYP2C19) expression in adjacent normal and tumor tissues in Chinese cancer patients Med Sci Monit 12 May (5) 2006 BR174 BR178
17. W. Remmele, and K.H. Schicketanz Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer Computer-assisted image analysis (QIC score) vs. subjective grading (IRS) Pathol Res Pract 189 1993 862 866
18. W. Remmele, and H.E. Stegner Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue Pathologe 8 1987 138 140
19. I. Bergheim, E. Wolfgarten, E. Bollschweiler, A.H. Hölscher, C. Bode, and A. Parlesak Cytochrome P450 levels are altered in patients with esophageal squamous-cell carcinoma World J Gastroenterol 13 7 2007 997 1002
20. S. Ozawa, B. Schoket, and L.P. McDaniel Analyses of bronchial bulky DNA adduct levels and CYP2C9, GSTP1 and NQO1 genotypes in a Hungarian study population with pulmonary diseases Carcinogenesis 20 6 1999 991 995
21. M. Degawa, S.J. Stern, and M.V. Martin Metabolic activation and carcinogen-DNA adduct detection in human larynx Cancer Res 54 September (18) 1994 4915 4919
22. L. Zhang, J. Tu, Z.L. Yu, Y.D. Wu, C.M. Xu, and S.T. Zhang Effects of the inhibition of cyclooxygenase-2 on human esophageal cancer cells: inhibition of cell proliferation and induction of apoptosis Pathol Oncol Res July 2009
23. E. Piazuelo, P. Jiménez, and M. Strunk Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus Prostaglandins Other Lipid Mediat 81 December (3-4) 2006 150 161
24. R.F. Souza, K. Shewmake, D.G. Beer, B. Cryer, and S.J. Spechler Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells Cancer Res 60 October (20) 2000 5767 5772
25. A. Hoque, S.M. Lippman, and T.T. Wu Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention Carcinogenesis 26 April (4) 2005 785 791
26. D.D. de Carvalho, A. Sadok, and V. Bourgarel-Rey Nox1 downstream of 12-lipoxygenase controls cell proliferation but not cell spreading of colon cancer cells Int J Cancer 122 April (8) 2008 1757 1764
27. S. Saini, H. Hirata, S. Majid, and R. Dahiya Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis Cancer Res 69 September (17) 2009 7038 7045
28. C.L. Chang, E. Hong, P. Lao-Sirieix, and R.C. Fitzgerald A novel role for the retinoic acid-catabolizing enzyme CYP26A1 in Barrett's associated adenocarcinoma Oncogene 27 May (21) 2008 2951 2960
29. U.R. Michaelis, J.R. Falck, R. Schmidt, R. Busse, and I. Fleming Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells Arterioscler Thromb Vasc Biol 25 February (2) 2005 321 326
30. H. Zhi, L. Wang, and J. Zhang Significance of COX-2 expression in human esophageal squamous cell carcinoma Carcinogenesis 27 June (6) 2006 1214 1221